Schwab Charles Investment Management Inc. Buys 53,821 Shares of Juno Therapeutics Inc (JUNO)

Schwab Charles Investment Management Inc. grew its stake in shares of Juno Therapeutics Inc (NASDAQ:JUNO) by 16.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 378,195 shares of the biopharmaceutical company’s stock after buying an additional 53,821 shares during the period. Schwab Charles Investment Management Inc. owned 0.33% of Juno Therapeutics worth $17,288,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company increased its position in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. Advisor Group Inc. increased its position in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,439 shares in the last quarter. QS Investors LLC purchased a new position in Juno Therapeutics during the second quarter worth $135,000. Bronfman E.L. Rothschild L.P. increased its position in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 3,559 shares in the last quarter. Finally, Wellington Shields & Co. LLC purchased a new position in Juno Therapeutics during the third quarter worth $202,000. 71.49% of the stock is owned by institutional investors.

In related news, Director Richard Klausner sold 36,000 shares of Juno Therapeutics stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $1,611,360.00. Following the transaction, the director now owns 744,392 shares in the company, valued at $33,318,985.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Hans Edgar Bishop sold 270,250 shares of Juno Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The disclosure for this sale can be found here. Insiders have sold 473,031 shares of company stock worth $27,031,205 in the last 90 days. Insiders own 15.08% of the company’s stock.

Several equities analysts have weighed in on the company. Raymond James Financial reissued a “buy” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Barclays downgraded Juno Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $55.00 to $87.00 in a research report on Wednesday, January 24th. Wells Fargo & Co downgraded Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Finally, Maxim Group reissued a “buy” rating and set a $56.00 price target on shares of Juno Therapeutics in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $51.20.

Shares of Juno Therapeutics Inc (NASDAQ:JUNO) opened at $86.56 on Friday. Juno Therapeutics Inc has a fifty-two week low of $19.62 and a fifty-two week high of $86.76. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $9,880.00, a price-to-earnings ratio of -25.53 and a beta of 3.42.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/02/23/schwab-charles-investment-management-inc-buys-53821-shares-of-juno-therapeutics-inc-juno.html.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply